Shirley Ding S L, Leow S N, Munisvaradass R, Koh E H, Bastion M L C, Then K Y, Kumar S, Mok P L
Department of Biomedical Science, Faculty of Medicine and Health Sciences, Universiti Putra Malaysia, UPM Serdang, Selangor, Malaysia.
Department of Ophthalmology, Hospital Sultanah Aminah, Johor Bahru, Malaysia.
Eye (Lond). 2016 Oct;30(10):1293-1309. doi: 10.1038/eye.2016.94. Epub 2016 Jun 10.
Erythropoietin (EPO) is a glycoprotein hormone conventionally thought to be responsible only in producing red blood cells in our body. However, with the discovery of the presence of EPO and EPO receptors in the retinal layers, the EPO seems to have physiological roles in the eye. In this review, we revisit the role of EPO in the eye. We look into the biological role of EPO in the development of the eye and the physiologic roles that it has. Apart from that, we seek to understand the mechanisms and pathways of EPO that contributes to the therapeutic and pathological conditions of the various ocular disorders such as diabetic retinopathy, retinopathy of prematurity, glaucoma, age-related macular degeneration, optic neuritis, and retinal detachment. With these understandings, we discuss the clinical applications of EPO for treatment of ocular disorders, modes of administration, EPO formulations, current clinical trials, and its future directions.
促红细胞生成素（EPO）是一种糖蛋白激素，传统上认为它仅负责在我们体内产生红细胞。然而，随着视网膜各层中促红细胞生成素（EPO）及其受体的发现，EPO似乎在眼睛中具有生理作用。在这篇综述中，我们重新审视EPO在眼睛中的作用。我们研究EPO在眼睛发育中的生物学作用及其所具有的生理作用。除此之外，我们试图了解EPO导致各种眼部疾病（如糖尿病性视网膜病变、早产儿视网膜病变、青光眼、年龄相关性黄斑变性、视神经炎和视网膜脱离）治疗和病理状况的机制和途径。基于这些认识，我们讨论EPO在眼部疾病治疗中的临床应用、给药方式、EPO制剂、当前的临床试验及其未来方向。
